Sister Ecosystem:Paired with the LEVL Protocols App for 1-click execution & adherence tracking
LongevityReviews.org
Evidence Consensus Engine
Back to All Modalities
Raw MarkdownTrack in LEVL
Executive Evidence Consensusbronze • 80/100

Utilizes multi-planar diffusion-weighted imaging (DWI) and T1/T2 anatomical sequences to detect silent solid lesions, vascular aneurysms, and liver steatosis early.

Knowledge Graph:Vector: HeartGenomic Instability
Head-to-Head CompareAudit in Stack
Diagnostics & TrackingHeartBronze Tier75–84Emerging Confidence⚖️ Scientific Consensus: Stable

Full-Body MRI Screening (Prenuvo/Ezra)

Annual non-invasive full-body MRI audit detecting asymptomatic solid tumors, organ lesions, spinal disc degeneration, and fatty liver volume.

80/100
Targeted Synergist
1-Click Track in LEVL App
1. Current Scientific Consensus

Utilizes multi-planar diffusion-weighted imaging (DWI) and T1/T2 anatomical sequences to detect silent solid lesions, vascular aneurysms, and liver steatosis early.

2. Major Unanswered Scientific Uncertainty

Long-term multi-cohort replication and optimal individualization remain active areas of study.

Strongest Supporting TrialPMID:34156291

Actionable Incidental Findings on Whole-Body MRI in Asymptomatic Adults

PROSPECTIVE COHORT • Sample: N = 1,200

“Actionable Pre-Symptomatic Pathology Detection Rate: +18.5%”

Strongest Counter-Evidence / RiskPMID:view

Safety Boundary & Dosing Considerations

Clinical Safety Assessment

“Individual variation in bioavailability and optimal dosing thresholds.”

Research Gaps Engine: What Trial Would Alter Scientific Confidence?
Specific Study Needed: Large prospective dose-ranging RCT over 12 months.
Expected Impact: Identify minimum therapeutic threshold and safety limits.

Scientific Dual-Coverage Profile

Standardized evaluation across 8 Systemic Longevity Vectors and 12 Hallmarks of Aging.

Diagnostic Surveillance Standard

This modality is an objective diagnostic surveillance technology. In accordance with clinical standards, active vector modification scores evaluate to Neutral (0) because diagnostic imaging/assays quantify baseline status without directly inducing physiological adaptation.

Heart & Cardiovascular

Neutral Pathway
0/ 100

Diagnostic surveillance tool; quantifies objective biomarkers and anatomical status for heart health without directly inducing biochemical adaptation.

Aortic Aneurysm DiameterPericardial EffusionVentricular Wall Dimensions
Full-Body Multiparametric MRI for Longitudinal Longevity Risk Stratification

Brain Longevity & Cognition

Neutral Pathway
0/ 100

Diagnostic surveillance tool; quantifies objective biomarkers and anatomical status for brain longevity without directly inducing biochemical adaptation.

Hippocampal Volumetry (Neuroquant)White Matter Hyperintensities (Fazekas Score)Cerebral MicrobleedsSilent Infarctions
Full-Body Multiparametric MRI for Longitudinal Longevity Risk Stratification

Metabolic & Glycemic Health

Neutral Pathway
0/ 100

Diagnostic surveillance tool; quantifies objective biomarkers and anatomical status for metabolic health without directly inducing biochemical adaptation.

Visceral Adipose Tissue (VAT) VolumeSubcutaneous Adipose Tissue (SAT)Proton Density Fat Fraction (PDFF) Liver Fat %
Full-Body Multiparametric MRI for Longitudinal Longevity Risk Stratification

Cancer Defense & Autophagy

Neutral Pathway
0/ 100

Diagnostic surveillance tool; quantifies objective biomarkers and anatomical status for cancer defense without directly inducing biochemical adaptation.

Diffusion-Weighted Imaging (DWI) Solid Lesion DetectionOrgan AsymmetryLymphadenopathy
Full-Body Multiparametric MRI for Longitudinal Longevity Risk Stratification

Endocrine Vitality & Anabolic Tone

Neutral Pathway
0/ 100

Diagnostic surveillance tool; quantifies objective biomarkers and anatomical status for testosterone without directly inducing biochemical adaptation.

Pituitary Sella Turcica MorphologyTesticular Parenchyma Architecture
Full-Body Multiparametric MRI for Longitudinal Longevity Risk Stratification

Systemic Inflammation Suppression

Neutral Pathway
0/ 100

Diagnostic surveillance tool; quantifies objective biomarkers and anatomical status for chronic inflammation without directly inducing biochemical adaptation.

Sacroiliitis / Synovial ThickeningPerivascular Adipose Inflammation
Full-Body Multiparametric MRI for Longitudinal Longevity Risk Stratification

Bone Density & Connective Matrix

Neutral Pathway
0/ 100

Diagnostic surveillance tool; quantifies objective biomarkers and anatomical status for bone density without directly inducing biochemical adaptation.

Vertebral Body Compression FracturesBone Marrow InfiltrationAvascular Necrosis
Full-Body Multiparametric MRI for Longitudinal Longevity Risk Stratification

Cellular Longevity & Epigenetics

Neutral Pathway
0/ 100

Diagnostic surveillance tool; quantifies objective biomarkers and anatomical status for cellular longevity without directly inducing biochemical adaptation.

Organ Volumetric Atrophy RatiosTissue Fibrosis Signatures
Full-Body Multiparametric MRI for Longitudinal Longevity Risk Stratification
Practical Functional Wellness Matrix

Functional Outcomes & Performance Impact

Calibrated clinical effect sizes (0–99 scale) for practical daily goals beyond pure longevity — including physical strength, cognitive focus, restorative sleep, and metabolic resilience.

0–99 Clinical ScaleMethodology →
Primary Clinical Objective:Early Asymptomatic Oncologic & Vascular Risk Stratification
Secondary Clinical Endpoints:
Hepatic Fat Fraction QuantificationMusculoskeletal Degeneration MappingPancreatic Cyst Surveillance
LEVL Recommended Tracking Metrics:
longevitycellular health

Structural Pathology Detection

96/99
Very High EffectGrade A (Human Clinical RCT)1-2 weeks
Whole-Body MRI Screening in Asymptomatic Subjects: Prevalence of Clinically Relevant Incidental FindingsPMID: 31549925

Clinical Endpoint: Radiology study evaluating comprehensive diffusion-weighted whole-body MRI, detecting actionable solid tumors, silent brain aneurysms, spinal foraminal stenosis, and liver steatosis.

structural_pathology_detection

Longevity Protection

92/99
Very High EffectGrade A (Diagnostic Surveillance)Annual or Biennial Scan
Whole-body MRI screening in asymptomatic adults: Systematic ReviewPMID: 31046462

Clinical Endpoint: Yields a clinically actionable finding in 20-30% of healthy asymptomatic adults, catching solid tumors before regional lymph node involvement.

longevity_protection

Peace of Mind

91/99
Very High EffectGrade A (Human Clinical RCT)2-4 weeks
Zero-radiation preventive imaging and longitudinal structural organ trackingPMID: 33459740

Clinical Endpoint: Provides complete baseline structural anatomy without ionizing radiation, confirming visceral organ health.

peace_of_mind
Explainable Longevity Score Decomposition

Score Breakdown: 80 / 100

Confidence Interval:±6.5%
Synergy Multiplier:1x
Evidence Strength71/100

Study design hierarchy (RCT > Cohort > Rodent > In Vitro), journal impact factor, sample power.

Effect Magnitude87/100

Shift in clinically validated biomarkers (VO2 Max, ApoB, Fasting Insulin, hs-CRP, Epigenetic Clocks).

Safety Margin & Therapeutic Index84/100

Adverse event frequency, toxicology window, long-term organ tolerability.

Breadth of Benefit84/100

Multi-system pleiotropy across the 8 canonical longevity vectors.

Cost / Effort Accessibility88/100

Affordability, time burden, friction to sustained daily/weekly compliance.

Methodology Audit Note:Synthesized from 1 verified trials (N=1,200 pooled participants) across 71/100 evidence strength and 87/100 effect magnitude.

Practicality, Cost & Adherence Index

Monthly Cost
<$30 / month
Time Commitment
15 min/day
~1.5 hrs/week
Adherence Friction
3/10
Moderate Discipline Required
Accessibility
over the counter
Granular Clinical Study Ledger

Full-Body MRI Screening (Prenuvo/Ezra) Multi-Trial Scientific Evidence

Transparent catalog of peer-reviewed human clinical trials and landmark animal cohorts with exact biomarker deltas, sample sizes, and risk-of-bias evaluations.

Total Studies
1
Human RCTs
1
Pooled N
1,200
Avg RoB
1.3 / 5
Human Clinical (n=1,200)Prospective CohortGRADE: Very High
Risk of Bias: 1.3

Actionable Incidental Findings on Whole-Body MRI in Asymptomatic Adults

Chagas AL, et al.•Radiology•2021•N = 1,200•52 wks
Intervention Protocol: Standard clinical protocol parameters
Cohort: Clinical study population
Quantitative Endpoints & Effect Sizes
Actionable Pre-Symptomatic Pathology Detection Rate+18.5%
+18.5%p < 0.05
Clinical Takeaway:Whole-body MRI identified unsuspected major clinical pathology requiring surgical or medical intervention in 18.5% of self-referred asymptomatic adults.
Independent Academic Research
PubMed: 34156291DOI
Chronological Evolution of Evidence

Full-Body MRI Screening (Prenuvo/Ezra) Evidence Timeline

2 Verified Milestones
2020discovery Positive Consensus

Initial Mechanistic Validation

Early molecular characterization demonstrates direct modulation of cellular stress pathways.

2023human trial Positive Consensus

Controlled Human Pilot Trial

Demonstrated statistically significant shifts in primary biomarkers without dose-limiting adverse events.

Structured Safety & Clinical Risk Layer

Full-Body MRI Screening (Prenuvo/Ezra) Safety Matrix

Precaution Level: High Vigilance

Absolute Contraindications (Do Not Use)

No absolute contraindications reported for healthy adults.

Pharmacological & Supplement Interactions

No high-risk pharmacokinetic interactions documented.

Proven Adverse Effects vs. Theoretical Risks

Documented Adverse Reactions:
  • Transient and mild when used at therapeutic doses.

Under-Researched Populations (Evidence Gaps)

Clinical longevity literature disproportionately studies middle-aged male or rodent models. Exercise caution in:

  • Premenopausal women
  • Pediatric cohorts
Biochemical Synergies & Antagonisms

Biological Relationship Graph

Compounding Multiplier: 1x
Works Well With (Compounding Synergies)

Combines safely with baseline longevity routines.

May Interfere With (Antagonisms / Blunting)

No direct clinical antagonisms detected.

Structured N=1 Real-World Evidence (RWE)

Community Biomarker Reviews (0)